Ocular Therapeutix Company Profile (NASDAQ:OCUL)

About Ocular Therapeutix (NASDAQ:OCUL)

Ocular Therapeutix logoOcular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company's bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OCUL
  • CUSIP: N/A
  • Web: www.ocutx.com
Capitalization:
  • Market Cap: $320.18 million
  • Outstanding Shares: 29,028,000
Average Prices:
  • 50 Day Moving Avg: $9.20
  • 200 Day Moving Avg: $8.67
  • 52 Week Range: $4.04 - $12.43
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.74
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $1.9 million
  • Price / Sales: 168.52
  • Book Value: $2.21 per share
  • Price / Book: 4.99
Profitability:
  • EBIDTA: ($47,550,000.00)
  • Net Margins: -2,346.47%
  • Return on Equity: -56.23%
  • Return on Assets: -44.41%
Debt:
  • Debt-to-Equity Ratio: 0.19%
  • Current Ratio: 9.32%
  • Quick Ratio: 9.31%
Misc:
  • Average Volume: 879,260 shs.
  • Beta: 1.54
  • Short Ratio: 5.24
 

Frequently Asked Questions for Ocular Therapeutix (NASDAQ:OCUL)

What is Ocular Therapeutix's stock symbol?

Ocular Therapeutix trades on the NASDAQ under the ticker symbol "OCUL."

How were Ocular Therapeutix's earnings last quarter?

Ocular Therapeutix Inc (NASDAQ:OCUL) released its earnings results on Friday, May, 5th. The company reported ($0.58) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.10. The firm earned $0.48 million during the quarter, compared to analysts' expectations of $0.51 million. Ocular Therapeutix had a negative net margin of 2,346.47% and a negative return on equity of 56.23%. During the same quarter in the previous year, the business earned ($0.35) EPS. View Ocular Therapeutix's Earnings History.

Where is Ocular Therapeutix's stock going? Where will Ocular Therapeutix's stock price be in 2017?

6 brokerages have issued 1-year price objectives for Ocular Therapeutix's stock. Their predictions range from $5.84 to $60.00. On average, they anticipate Ocular Therapeutix's stock price to reach $26.97 in the next twelve months. View Analyst Ratings for Ocular Therapeutix.

What are analysts saying about Ocular Therapeutix stock?

Here are some recent quotes from research analysts about Ocular Therapeutix stock:

  • 1. According to Zacks Investment Research, "Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts. " (5/23/2017)
  • 2. Cantor Fitzgerald analysts commented, "We are initiating on Ocular Therapeutix with an Overweight rating and $35 Price target. We believe Ocular's portfolio of sustained release therapies have the potential to treat an array of ophthalmic conditions with significant unmet need. In focus, we view the upcoming FDA decision this year for lead developmental candidate DEXTENZA' in post-surgical ocular pain as a meaningful catalyst for the shares, and estimate that DEXTENZA could reach annual sales of $600 million at peak market penetration in 2023, with further growth to $900 million by 2030 for this indication alone in the U.S." (2/9/2017)

Who are some of Ocular Therapeutix's key competitors?

Who owns Ocular Therapeutix stock?

Ocular Therapeutix's stock is owned by a number of of retail and institutional investors. Top institutional investors include Jennison Associates LLC (11.19%), Versant Venture Management LLC (7.70%), SV Health Investors LLC (5.58%), FMR LLC (4.75%), Wellington Management Group LLP (4.56%) and Columbus Circle Investors (3.78%). Company insiders that own Ocular Therapeutix stock include Amarpreet Sawhney, Charles M Warden, James Fortune and Svlsf Iv, Llc. View Institutional Ownership Trends for Ocular Therapeutix.

Who sold Ocular Therapeutix stock? Who is selling Ocular Therapeutix stock?

Ocular Therapeutix's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Polaris Venture Management Co. V L.L.C., Bailard Inc., Renaissance Technologies LLC, Credit Suisse AG, Goldman Sachs Group Inc., Dynamic Technology Lab Private Ltd and Bank of Montreal Can. View Insider Buying and Selling for Ocular Therapeutix.

Who bought Ocular Therapeutix stock? Who is buying Ocular Therapeutix stock?

Ocular Therapeutix's stock was bought by a variety of institutional investors in the last quarter, including Columbus Circle Investors, JPMorgan Chase & Co., Wellington Management Group LLP, Deltec Asset Management LLC, Morgan Stanley, Vanguard Group Inc., SG Americas Securities LLC and NEXT Financial Group Inc. View Insider Buying and Selling for Ocular Therapeutix.

How do I buy Ocular Therapeutix stock?

Shares of Ocular Therapeutix can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Ocular Therapeutix stock cost?

One share of Ocular Therapeutix stock can currently be purchased for approximately $11.03.

Analyst Ratings

Consensus Ratings for Ocular Therapeutix (NASDAQ:OCUL) (?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $26.97 (144.55% upside)

Analysts' Ratings History for Ocular Therapeutix (NASDAQ:OCUL)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017Cantor FitzgeraldReiterated RatingOverweight$35.00LowView Rating Details
5/15/2017BTIG ResearchDowngradeBuy -> NeutralLowView Rating Details
3/13/2017Cowen and CompanyReiterated RatingOutperform$60.00MediumView Rating Details
11/15/2016Royal Bank of CanadaReiterated RatingOutperform$30.00 -> $32.00N/AView Rating Details
8/11/2016JMP SecuritiesInitiated CoverageOutperform$21.00 -> $5.84N/AView Rating Details
6/7/2016Morgan StanleyReiterated RatingOverweight$17.00 -> $16.00N/AView Rating Details
8/5/2015NomuraInitiated CoverageBuy$46.00N/AView Rating Details
(Data available from 5/27/2015 forward)

Earnings

Earnings History for Ocular Therapeutix (NASDAQ:OCUL)
Earnings by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Earnings History by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.48)($0.58)$0.51 million$0.48 millionViewN/AView Earnings Details
3/10/2017Q4 2016($0.45)($0.52)$0.48 million$0.51 millionViewN/AView Earnings Details
11/9/2016Q316($0.50)($0.39)$0.47 million$0.48 millionViewListenView Earnings Details
8/9/2016Q216($0.49)($0.46)$0.55 million$0.44 millionViewListenView Earnings Details
5/10/2016Q116($0.43)($0.44)$458.00 millionViewListenView Earnings Details
3/10/2016Q415($0.47)($0.43)$0.44 millionViewListenView Earnings Details
11/10/2015Q315($0.38)($0.47)$0.43 millionViewListenView Earnings Details
8/10/2015Q215($0.33)($0.45)$0.46 millionViewListenView Earnings Details
5/15/2015Q115($0.39)($0.35)$0.30 million$0.43 millionViewListenView Earnings Details
3/10/2015Q4($0.38)($0.37)$0.20 million$0.51 millionViewListenView Earnings Details
11/12/2014Q3 14($0.55)($0.48)$0.10 million$0.14 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ocular Therapeutix (NASDAQ:OCUL)
Current Year EPS Consensus Estimate: $-2.35 EPS
Next Year EPS Consensus Estimate: $-1.92 EPS

Dividends

Dividend History for Ocular Therapeutix (NASDAQ:OCUL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ocular Therapeutix (NASDAQ:OCUL)
Insider Ownership Percentage: 30.60%
Institutional Ownership Percentage: 66.59%
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Institutional Ownership by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Insider Trades by Quarter for Ocular Therapeutix (NASDAQ:OCUL)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/15/2016Amarpreet SawhneyInsiderBuy45,300$7.85$355,605.00View SEC Filing  
6/9/2016Amarpreet SawhneyCEOBuy10,000$6.70$67,000.00View SEC Filing  
11/17/2015Amarpreet SawhneyCEOBuy10,000$8.25$82,500.00View SEC Filing  
9/15/2015James FortuneCOOSell9,470$17.16$162,505.20View SEC Filing  
9/14/2015Amarpreet SawhneyCEOBuy15,000$16.50$247,500.00View SEC Filing  
6/15/2015Charles M WardenDirectorSell320,000$22.00$7,040,000.00View SEC Filing  
6/10/2015Charles M WardenDirectorSell427,000$22.00$9,394,000.00View SEC Filing  
6/10/2015Svlsf Iv, LlcMajor ShareholderSell1,119,000$22.00$24,618,000.00View SEC Filing  
7/30/2014Amarpreet SawhneyCEOBuy76,922$13.00$999,986.00View SEC Filing  
7/30/2014Svlsf Iv, LlcMajor ShareholderBuy715,380$13.00$9,299,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ocular Therapeutix (NASDAQ:OCUL)
Latest Headlines for Ocular Therapeutix (NASDAQ:OCUL)
Source:
DateHeadline
bizjournals.com logoGlaucoma Pipeline Market 2017 Covering Therapeutics Development Stage and Drug Profiles Analysis
www.bizjournals.com - May 24 at 7:11 PM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 23 at 7:48 AM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Upgraded at Zacks Investment Research
www.americanbankingnews.com - May 16 at 7:32 AM
americanbankingnews.com logoCantor Fitzgerald Weighs in on Ocular Therapeutix Inc's FY2017 Earnings (OCUL)
www.americanbankingnews.com - May 12 at 12:33 PM
streetinsider.com logoOcular Therapeutix (OCUL) Reports Phase 3 Data for DEXTENZA for ARVO Meetings - StreetInsider.com
www.streetinsider.com - May 11 at 9:10 AM
finance.yahoo.com logoOcular Therapeutix™ Presented Phase 3 Data for DEXTENZA™ at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
finance.yahoo.com - May 11 at 9:09 AM
fool.com logoWhy Ocular Therapeutix Inc Stock Jumped Higher Today - Motley Fool
www.fool.com - May 11 at 12:13 AM
businesswire.com logoOcular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX ...
www.businesswire.com - May 9 at 6:35 PM
finance.yahoo.com logoOcular Therapeutix™ Presents Preclinical Data on Pharmacokinetics, Efficacy and Tolerability of Sustained Release Intravitreal Tyrosine Kinase Inhibitor Hydrogel Depot (OTX-TKI) at the ARVO Annual Meeting
finance.yahoo.com - May 9 at 6:35 PM
americanbankingnews.com logoOcular Therapeutix (OCUL) Given Media Impact Rating of 0.15
www.americanbankingnews.com - May 8 at 11:44 PM
benzinga.com logoOcular Therapeutix's Manufacturing Inspection: Items Of Concern Are 'Addressable,' Shouldn't Delay Product Launch
www.benzinga.com - May 8 at 6:25 PM
fool.com logoWhy Ocular Therapeutix Inc Stock Jumped Higher Today
www.fool.com - May 8 at 1:43 PM
finance.yahoo.com logoOcular Therapeutix™ Presents Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
finance.yahoo.com - May 8 at 12:12 PM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: ImmunoGen and Ocular Therapeutix
finance.yahoo.com - May 8 at 12:12 PM
finance.yahoo.com logoEdited Transcript of OCUL earnings conference call or presentation 5-May-17 12:30pm GMT
finance.yahoo.com - May 7 at 9:06 AM
finance.yahoo.com logoOcular Therapeutix™ Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 6 at 6:53 PM
finance.yahoo.com logoInvestor Network: Ocular Therapeutix Inc to Host Earnings Call
finance.yahoo.com - May 6 at 6:53 PM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Cut to "Neutral" at BTIG Research
www.americanbankingnews.com - May 6 at 11:02 AM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Earns Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - May 5 at 10:50 PM
americanbankingnews.com logoOcular Therapeutix (OCUL) Receives Daily Media Impact Rating of 0.27
www.americanbankingnews.com - May 5 at 10:35 PM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS
www.americanbankingnews.com - May 5 at 9:38 PM
prnewswire.com logoResearch Reports Initiation on Biotech Stocks -- Trevena, Ocular Therapeutix, INSYS Therapeutics, and Pain ... - PR Newswire (press release)
www.prnewswire.com - May 5 at 8:57 AM
streetinsider.com logoForm 8-K OCULAR THERAPEUTIX, INC For: May 05 - StreetInsider.com
www.streetinsider.com - May 5 at 8:57 AM
marketbeat.com logoOcular Therapeutix reports 1Q loss
marketbeat.com - May 5 at 7:42 AM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Scheduled to Post Earnings on Friday
www.americanbankingnews.com - May 3 at 9:58 AM
finance.yahoo.com logoOcular Therapeutix™ to Present Data on Anterior and Posterior Segment Drug Product Candidates at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
finance.yahoo.com - May 2 at 11:14 AM
businesswire.com logoOcular Therapeutix™ to Report First Quarter 2017 Financial Results ... - Business Wire (press release)
www.businesswire.com - May 1 at 5:54 PM
finance.yahoo.com logoOcular Therapeutix™ to Report First Quarter 2017 Financial Results
finance.yahoo.com - May 1 at 5:54 PM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 28 at 10:36 AM
americanbankingnews.com logoOcular Therapeutix (OCUL) Receiving Positive Press Coverage, Analysis Finds
www.americanbankingnews.com - April 28 at 12:28 AM
marketwatch.com logoFormer FDA Official to Conduct Popular ComplianceOnline Seminar on FDA's GMP Expectations for Phase I and First-in-Man Clinical Trials
www.marketwatch.com - April 26 at 6:17 PM
businesswire.com logoOcular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS ...
www.businesswire.com - April 24 at 6:50 PM
streetinsider.com logoOcular Therapeutix (OCUL) to Announce Additional Phase 3 Data & Patient Reported Outcomes Results for DEXTENZA at ASCRS Conference
www.streetinsider.com - April 24 at 6:50 PM
finance.yahoo.com logoETFs with exposure to Ocular Therapeutix, Inc. : April 24, 2017
finance.yahoo.com - April 24 at 6:50 PM
americanbankingnews.com logoOcular Therapeutix (OCUL) Earning Positive News Coverage, Study Shows
www.americanbankingnews.com - April 24 at 4:56 PM
finance.yahoo.com logoOcular Therapeutix™ to Present Additional Phase 3 Data and ... - Yahoo Finance
finance.yahoo.com - April 24 at 1:50 PM
finance.yahoo.com logoOcular Therapeutix™ to Present Additional Phase 3 Data and Patient Reported Outcomes Results for DEXTENZA™ at the American Society of Cataract and Refractive Surgery (ASCRS) Symposium
finance.yahoo.com - April 24 at 1:50 PM
americanbankingnews.com logoOcular Therapeutix (OCUL) Earning Positive Press Coverage, Report Shows
www.americanbankingnews.com - April 21 at 12:33 AM
americanbankingnews.com logoOcular Therapeutix (OCUL) Earning Positive News Coverage, Report Shows
www.americanbankingnews.com - April 17 at 4:26 PM
streetinsider.com logoOcular Therapeutix (OCUL) Names George Migausky as Interim CFO
www.streetinsider.com - April 7 at 7:24 PM
streetinsider.com logoOcular Therapeutix (OCUL) Names George Migausky as Interim CFO - StreetInsider.com
www.streetinsider.com - April 7 at 11:41 AM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 3 at 1:41 PM
americanbankingnews.com logoResearch Analysts Offer Predictions for Ocular Therapeutix Inc's FY2017 Earnings (OCUL)
www.americanbankingnews.com - March 23 at 10:16 AM
americanbankingnews.com logoOcular Therapeutix Inc (OCUL) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 8:53 AM
americanbankingnews.com logoZacks Investment Research Upgrades Ocular Therapeutix Inc (OCUL) to "Hold"
www.americanbankingnews.com - March 22 at 8:34 PM
wsj.com logoCFO Moves: Ocular Therapeutix, Conatus Pharmaceuticals
blogs.wsj.com - March 22 at 9:08 AM
americanbankingnews.com logoBTIG Research Reiterates Buy Rating for Ocular Therapeutix Inc (OCUL)
www.americanbankingnews.com - March 21 at 9:25 PM
streetinsider.com logoPre-Open Movers 03/21: (PTIE) (HTBX) (ESPR) Higher; (CALA) (OCUL) (GEL) Lower (more...)
www.streetinsider.com - March 21 at 6:50 PM
biz.yahoo.com logoOCULAR THERAPEUTIX, INC Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - March 20 at 5:05 PM
americanbankingnews.com logoZacks Investment Research Lowers Ocular Therapeutix Inc (OCUL) to Sell
www.americanbankingnews.com - March 18 at 5:00 PM

Social

Chart

Ocular Therapeutix (OCUL) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by MarketBeat.com Staff